ANTIGENIC VARIANTS OF INFLUENZA A VIRUS (PR8 STRAIN) : I. THEIR DEVELOPMENT DURING SERIAL PASSAGE IN THE LUNGS OF PARTIALLY IMMUNE MICE by Gerber, Paul et al.
ANTIGENIC VARIANTS OF INFLUENZA A VIRUS (PR8 STRAIN) 
I.  THEIR DEVELOPMENT DURING SERIAL  PASSAGE IN  THE LUNGS OF PARTIALLY 
IMMUNE MICE* 
BY PAUL GERBER, CLAYTON G. LOOSLI, M.D.,  AHO DOROTHY  HAMRE, I~.D. 
(From the Section of Preventive Medicine, Departments of Medicine and Microbiology, 
The University of Chicago Schoo~ of Medicine, Ckicago) 
P~TES 44 AND 45 
(Received for publication, January 26, 1955) 
The  survival  of human influenza viruses  in  nature  in  the  presence  of a 
relatively high herd immunity due to prior infection or immunization has been 
attributed to the immunological instability of these agents (1-3). The partially 
immune hosts provide a selective environment for the emergence of antigenic 
variants capable of resisting neutralization by specific antibodies. This hypoth- 
esis, first advanced by Taylor (1)  in 1949, found experimental support by the 
work of Archetti and HorsfaU (4) who demonstrated the occurrence of antigenic 
changes during serial passage of influenza A viruses in fertile eggs in the presence 
of neutralizing antibodies to a related strain. This led to the present investiga- 
tion carried out in the routine host which allowed correlation of serological 
data with immunity and virulence since it is well established (5) that serological 
tests alone are insufficient for the evaluation of the significance of antigenic 
changes among influenza viruses. 
It has been shown previously that pulmonary influenza A virus infections 
can be produced in mice immunized with inactivated homologous virus (6, 7). 
The procedure employed in this study consisted of serial passage of mouse- 
adapted influenza A virus (PR8 strain) in the lungs of mice previously vacci- 
nated with formalin-inactivated homologous virus. This report describes the 
development  of  antigenic  variants  during  this  process.  Although  antigenic 
variation could be detected in earlier passage strains, the 17th and 21st strains 
were selected for a detailed study of their serological, immunological and growth 
characteristics. 
Materials  and Methods 
V/ruses.--The mouse-adapted  PR8 strain of influenza  A virus was employed.  This strain, 
originally obtained from Dr. Thomas  Francis, Jr., of the University  of Michigan,  Ann Arbor, 
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in  1941,  has  been maintained through continuous mouse lung passages in this laboratory 
and is highly pathogenic for mice both by  the air-borne and  intranasal routes of  infection. 
For the purpose of identification the laboratory stock of PR8 virus is referred to as PR8-S, 
the control passage strain as PR8-C and the strains passed serially in vaccinated mice are des- 
ignated as PR8-T strains. The figure following the "T" refers to the passage number. 
Stock _Passag6 Viru~.--Stock  passage virus (PR8-S) was prepared as previously described 
(8) by placing thirty mice in a  170 liter chamber and exposing them to dense lethal clouds of 
virus for 40 minutes. From 5 to 6 ml. of a 10 per cent mouse lung virus suspension was nebu- 
lized during the first 20 minutes, and the mice were allowed to breathe the infectious atmos- 
phere for another 20 minutes. After 48 hours the animals were sacrificed, the lungs removed 
aseptically and  ground  with sterile aiundum.  Antibiotic broth  (beef heart infusion broth 
containing penicillin and dihydrostreptomycin, 1,000 units and 1 rag. per ml., respectively, was 
added  to  make a  10 per cent suspension. Following centrifugation at  2,000  a.P.•,  for  10 
minutes the supernatant fluid was divided into aliquots quickly frozen and stored at --50°C. 
in an electric deep freeze. Such virus preparations usually had an EIDs0 titer of 109.5 and a 
mouse LDs0 titer of 107.0 to 107'5. 
Serial _Pa,  sage Viruses.--Parailel serial passages of PR8 virus were made in  immunized 
(PR8-T) and unimmunized (PR8-C) mice. In these series the mice were inoculated intrana- 
sally under light ether anesthesia with 0.05 ml. of a  10 per cent mouse lung suspension of the 
respective strains. The animals were then sacrificed 2 days after inoculation. The preparation 
of a suspension from a given passage was similar to that employed for preparing stock virus. 
Preparation of Virus Antigens for Hemagglutination (H.I.), Neutralization, and Absorption 
Tests.--Virns  antigens employed in these tests were prepared  by inoculating intra-allantoi- 
e.ally groups of ll-day-old fertile eggs with 0.2 ml. of a  10  -8 dilution of mouse lung suspension 
of the different passage strains. Only first egg passage fluids were used in all the experiments 
to avoid possible antigenic changes which may have resulted from repeated egg passages. 
Virus Titratlons.--For both mouse and egg infectivity tests serial tenfold dilutions of virus 
in antibiotic broth were prepared.  For egg infectivity titrations, 0.1  ml. from each dilution 
was inoculated into the allantoic cavity of a group of four D-day-old fertile eggs which were 
incubated at 36°C. for 48 hours. The eggs were then chilled and the aliantoic fluid from each 
egg was tested for agglutination of chicken red cells (9). Presence of hemagglutination indicated 
infection. The titers are expressed as the reciprocal of the dilutions calculated as the EID~ 
by the method of Reed  and Muench  (10).  Mouse infectivity tests were performed by in- 
tranasai inoculation under ether anesthesia of the 3- to 4- weck-old Swiss mice. Six mice were 
used per dilution each animal receiving 0.05  ml.  of the virus suspension. Deaths were re- 
corded for 10 days and the 50 per cent lethal dose (LD~0) was calculated by the method of 
Reed and Muench (10). 
In the air-borne experiments groups of mice were exposed to  100 and 1,000  50 per cent 
lethal air-borne doses of nebulized mouse lung virus suspension in a  170 liter cloud chamber. 
For the purpose of this study one 50 per cent lethal air-borne dose, hereafter referred to as 
LAD~0, is considered the smallest amount of nebulized mouse lung virus suspension which 
produces a fatal infection in 50 per cent of normal mice exposed to the infectious atmosphere 
for 40 minutes. 
Immunization of Mice.--Vacdnes were prepared from first egg passage ailantoic fluid virus 
treated with a  1 : 2000 dilution of formalin for 24 to 48 hours at 4°C. and tested for the loss of 
viability by egg inoculation. Each mouse received 0.1, 0.25,  or 0.5 ml. of vaccine intraper- 
itoneally depending on the degree of immunity desired. For the production of high antibody 
titers a second inoculation of 0.5 ml. was given a week later. All animals were challenged 10 
days after the last inoculation. This procedure was employed for both passage experiments 
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Preparation and Testing o/Antisera.--Groups of mice, hamsters, and ferrets were employed 
in the production of antisera against the different virus strains under study. Mice weighing 
25 to 28 gin. were inoculated intraperitoneally with 0.5 ml. of a 10  "a dilution of infected mouse 
lung  suspension.  Adult  Syrian  hamsters  were  infected  intranasally  under  light  ether  an- 
esthesia with 0.2 to 0.3 ml. of a 10  --~ dilution of the same virus suspension.  Adult ferrets were 
exposed to nebulized virus in a cloud chamber. Four to 5 ml. of a l0 s dilution of mouse lung 
virus suspension were atomized for a period of 15 minutes and the animals were allowed to re- 
main in this atmosphere for another 15 minute period. All animals were bled 2 to 3 weeks after 
inoculation or exposure and the sera kept frozen until used. 
The pattern  test was employed to determine the titer of hemagglutinin-inhibiting anti- 
body (11).  The tests were read after 60 minutes at 4°C. and the titers were expressed as the 
reciprocal of the highest initial serum dilution showing complete inhibition. Although non- 
specific inhibition of hemagglutination occurred only with ferret sera all sera were treated as 
routine with receptor-destroying enzyme (RDE) prepared according to the method of Tyrrell 
and Horsfall (12). 
The H.I. titer of individual immunized mice was determined from tail vein blood collected 
in white blood cell-counting pipettes previously rinsed with 0.I per cent heparin and dried be- 
fore use. The whole blood sample was diluted i: 10 with buffered saline and the cells removed 
by centrifugation. Since the average hematocrit value of adult mouse blood is about 50 per 
cent the plasma dilution was considered to be 1 : 20. 
For the titration of virus neutralizing antibodies the in ovo test of Hilleman and Horsfall 
(13) was used. The sera were diluted in threefold steps and mixed with an equal volume of 
virus dilution containing approximately 1,000 EIDto. 
Antibody  absorption.--The  method described by J'ensen and  Francis (14) was employed. 
It  consists  of coating formalinized,  washed  human  red  blood  cells with periodate-treated 
ailantoic fluid virus. Heterologous antibody was removed by single absorption with two ab- 
sorbing units of virus-coated erythrocytes at 4°C. for 16 to 18 hours. One absorbing unit is 
defined as the minimal volume of cell-virus complex capable of removing 64 units of homo- 
logous H.I. antibody (14). 
Serial Passage of PR8 Virus in Immunized M/ce.--Ten days following vaccination the mice 
were bled from the tail vein and the individual tLI. antibody titers determined as described 
above. Starting with animals with low H.I. antibody titers (1:40), a group of mice under light 
ether anesthesia were inoculated intranasally each with 0.05  ml. of a  10  -1 dilution of stock 
(PR8-S)  mouse lung virus suspension.  Mice with gradually increasing immune levels were 
selected for subsequent passages until virus growth could be maintained in the presence of high 
antibody titers (640-1280).  At the same time the original stock virus was passaged serially in 
unvaccinated, control mice (PRS-C) of the same age and lot as the test animals. After each 
passage, the animals were sacrificed  48 hours after challenge. The lungs from each group were 
perfused, pooled, ground, and suspended in antibiotic broth. Following determination of the 
virus content by egg infectivity titration the material was again inoculated undiluted  (10-1) 
intranasally into the next group of selected mice. This process was continued for 22 consecutive 
passages. 
RESULTS 
The  procedures  for  evaluating  antigenic  variation  consisted  of  (a)  cross- 
hemagghtination-inhibition  tests,  (b)  antibody absorption,  (c) in ovo neutrali- 
zation  tests,  (d)  cross-protection  tests  in mice,  and  (e)  comparison  of growth 
curves of the variant and stock virus strains in immune and non-immune mice, 
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H.I.  Tests.--The  results  of a  cross-hemagglutination-inhibition  test  with 
the 17th passage test virus strain (PR8-T17) are presented in Table I. It is evi- 
dent that  the control' (PRS-Cv)  and  stock  strain  (PR8-S)  are  serologicaUy 
identical which indicates that 17 serial passages of PR8 virus in non-immune 
mice had no effect on its antigenic character. On the other hand, 17 serial pas- 
sages of PR8 in vaccinated mice resulted in the selection of an antigenic variant 
which  was  only slightly inhibited by antisera  to  the  control or stock virus 
strains while the mouse, hamster, and ferret antisera to PRS-T17 virus inhibited 
to a much lesser extent the control and stock virus strains. This observation 
may be considered to indicate the extent to which the variant strain continues 
to share antigenic components with the original stock virus. 
TABLE I 
Cross-Hemagglutination-Inlff~tion Test with tke Parent (PR8-S) S~rain and Strains of Influen,.a 
A  Virus Serially Passed in Vaccinated (PRS-TxT) and Normal Mice (PRS-C) 
Mouse antisera  Hamster antisera  Ferret antisera 
Virus antigen 
PR8-Tt~  PR8-Ct7  PR8-S  PR8-TI7  PR8-C~7  PRS-S  PR8-TI¢  PRS-Ca7  PR8-S 
PR8-T17  256  8  8  256  16  16  512  64  64 
PRS-Cn  64  256  512  64  128  256  256  512  512 
PRS-S  64  256  512  64  128  256  256  512  512 
Titers are expressed  as the reciprocal  of the initial serum dilution. 
In order to determine whether the emergence of an apparently new antigenic 
character was a one step or multiple step phenomenon, strain-specific antisera 
were employed. These were readily prepared from convalescent hamster sera 
by the absorption technique of Jensen and Francis (14). H.I. tests using ab- 
sorbed and unabsorbed sera were then carried out simultaneously with the virus 
strains  obtained at  each passage  of PR8  virus in  vaccinated mice  (PRS-T 
series), with the 17th control passage strain (PR8-C17)  and the original stock 
virus (PRS-S). The results are shown in Text-fig. 1. The first 6 test passages 
are omitted since their antigenic character was identical with the 7th passage 
virus (PRS-T~). The right side of Text-fig. 1 shows the antibody titers against 
PRS-Tt7 antiserum before and after absorption with the control passage virus 
(PR8-C17). The shaded areas represent an antigenic component present at first 
in minor amounts and gradually increasing in quantity with continued passage 
of PR8 virus in vaccinated mice. The converse situation is shown at the left 
half of Text-fig. 1 giving the H.L titers against PR8-CI~ serum before and after 
absorption with PRS-T17 virus. Here the shaded areas indicate the gradually 
decreasing amounts of the PR8 component in the antigenic mosaic of the virus. 
The stepwise selection of antigenic variants reached a maximum between the 
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with the procedures employed. That this variant is stable and independent of 
the presence of a selective environment is shown by the persistence of the anti- 
genic  character of PR8-T,7 virus following  12 serial  passages in the lungs of 
non-immunized mice (PRS-T17N~). 
In Ovo Neutrali~.ation Tests.--Antigenic  analyses based entirely on in ~tro 
procedures  are  inadequate  since  neutralizing  and  hemagglutinin-inhibiting 
antibodies appear to be distinct  (15).  Cross-neutralization  tests in ovo were, 
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therefore, carried out and the results are shown in Table II. As can be seen, 
antisera  to PR8-C17 prepared in the three species of animals  employed had 
considerably  lower  neutralizing  antibodies  against  the  test  strain  PRS-TI~ 
which had undergone 17 passages in immunized mice than to the homologous 
(PRS-C17) virus. The persistence of a portion of the original PR8 component in 
the antigenic complex of the variant is again indicated by the extent of the 
cross-reactions between PR8-T1T antisera and the control virus strain.  These 
results confirm the data shown in Table I. 
Cross-Protection Test.--Two groups of forty mice each were vaccinated intra- 
peritoneally  with  two  doses of 0.5  ml.  of  formalin-inactivated  PR8-S  and 
PRS-Tx7 virus (aUantoic  fluid)  respectively. Prior to challenge  the uniformity 
and  level of the antibody response were ascertained in a  random sample of 
two-thirds of the population by determining the H.I. titers of individual mice. 
These ranged from 256 to 512. Groups of ten mice in each vaccine group and 632  ANTIGENIC  VARIANTS  OF  INFLUENZA  A  VIRUS 
the same number of control mice were then challenged intranasally with  100 
and 1,000 LDs0 doses of the variant and stock viruses. These virus suspensions 
had an LDs0 titer of 10  TM and 107.7 respectively. 48 hours following challenge 
three  mice  of each  group  were  sacrificed,  their  lungs  perfused  with  saline, 
pooled,  ground,  10  per  cent  suspensions  prepared  in  antibiotic  broth  and 
frozen at  -50°C. The virus titer of the respective lung suspensions was then 
TABLE II 
Cross-Neutralization Test in Eggs with Strains  of Influenza A  (PRg)  Virus Serially Passed 
in Vaccinaled (PRS-T17) and Normal Mice (PR8-C) 
Virus antigen 
PR8-Tx7 
PR8-Crt 
Mouse antisera  Hamster antisera  Ferret antisera 
PRS-TI,  PR8-Ca7  PRS-Tx7  PR8-Cn  PR8-Tt7  PR8-CI7 
288  9  452  64  270  129 
47  266  126  >905  156  4208 
50 per cent serum neutralizing titers are expressed as the reciprocal of the initial serum 
dilution. 
TABLE HI 
The Virus Content of tke Lungs at 48 Hours in Immunized and Control Mice Challenged with 
tke Stock and Passage T17 Strains of PR8 Virus 
Challenge virus 
PR8-S 
PRS-S 
PR8-T~7 
PR8-Tn 
Challenge 
dose LD~o 
intrsnssally 
100 
1000 
100 
1000 
EIDso titer of lungs 
Mice vaccinated with 
PRS-S  PRS-Tx7 
<1  3.7 
<1  <1 
7.5  <1 
Unvaccinated 
mice* 
8.8 
9.5 
8.5 
8.7 
* All remaining control mice died by the 6th day after challenge. 
determined by egg infectivity titration. The remaining mice were observed for 
a  period of 12 days after which  time the survivors were sacrificed and their 
lungs  examined  for lesions.  The  results  of  this  experiment are  recorded in 
Table ILl. 
It can be seen that all non-vaccinated control mice developed high virus titers 
in their lungs at 48 hours, and the remaining mice all died by the 6th day with 
extensive pulmonary consolidation.  There were  no  deaths,  however,  in  the 
vaccinated groups of mice challenged with either homologous or heterologous 
virus and no gross pulmonary changes were seen 12 days after challenge. No 
virus growth was detected when 100 LD60 doses of virus were employed in the 
homologous  or  heterologous challenges.  With  the  higher  dose  (1000  LD60) PAUL  GEILBER~  CLAYTON  G. LOOSLI,  AND  DOROTHY  ~R~  633 
solid immunity was indicated by the lack of virus growth following challenge 
with the respective homologous virus. As would be expected from the serologi- 
cal studies  (Tables I  and II, and Text-fig. 1) only limited virus growth (108n 
EIDs0) occurred in mice vaccinated with the variant PR8-Tt~ and challenged 
with 1000 LDs0 of PR8-S. On the other band, in spite of the absence of gross 
pulmonary changes at 48 hours, virus was present in significantly higher titer 
(10  ~'~ E~J)~0) in the lungs of mice vaccinated with PR8-S and challenged with 
1000 LDs0 of PR8-T17 virus (Table III). 
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TEx¢-FIO. 2.  Growth curves of PR8-S virus and its antigenic variant PR8-T~ in the 
lungs of immured mice (PR8-S vaccine) and nonqmmune controls. 
Comparison of Growth Curves and Pathology.--In order to demonstrate the 
actual virus growth and the associated gross and microscopic changes in the 
lungs of immunized and control mice resulting from infection with influenza 
virus the following experiments were designed. 
The air-borne route was chosen since it has been shown  previously to yield a more uniform 
infection (8) and because it also facilitates the use of a large number of animals. Two groups of 
120 mice each were vaccinated intraperitoneally with two doses of 0.25 mi. of formalin-in- 
activated PR8-S and PR8-T. allantoic fluid virus respectively. 120 control mice received the 
same volume of formalin-treated normal a|lantoic fluid. Ten days following vaccination the 
degree and uniformity of immune response were determined in a random sample of one-third 
of the total vaccinated group by testing the H.I. titers of individual mice. The titers ranged 
from 256 to 512. 
Half of each vaccinated and control group  was then exposed in a chamber to approximately 
1,000 lethal air-borne doses of PR8-T.  and  PRS-S respectively. At increasing intervals 634  ANTIGENIC  VARIANTS  OF  INFLUENZA  A  VIRUS 
following challenge, five  mice in each group were sacrificed, their lungs perfused with saline, 
pooled, ground, and 10 per cent suspensions prepared with antibiotic broth which were then 
stored at -50°C. At the same time two additional animals in each group were sacrificed and 
their lungs fixed for histopathologieal studies by intratracheal  injection of  Zenker-formol 
solution (16). Ten mice in each group were set aside to observe death and the surviving animals 
were sacrificed after 12 days. The virus content of the lungs was determined by egg infec- 
tivity titration. 
The comparative growth  curves of the  stock and  variant virus strains in 
immune and non-immune mice are shown in Text-figs. 2 and 3. Both the stock 
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and  variant strains  of PR8  virus grew rapidly in  the  lungs  of n0n-immune 
mice during the first 24 hours. The rates of multiplication of both strains during 
this period are almost identical as indicated by the slopes of the curves shown 
in  Text-figs. 2  and  3.  The variant strain,  however,  differed from  the  stock 
virus by failing to reach the same peak titer. 
All the non-immune animals infected with either virus died 4 to 5 days after 
exposure to the virus clouds. Extensive pulmonary consolidation was present 
in  the  gross.  Microscopically  there  was  no  difference  in  the  appearance  of 
pulmonary lesions produced  by the  PRS-S  virus or its variant PR8-T21.  As 
seen in  Figs.  1 and  2  both produced  at 4  days characteristic  and  extensive 
destruction  of the  bronchial  lining  cells and  extensive pulmonary exudation 
of edema fluid  and  leucocytes.  The peribronchial  connective tissue was also PAUL GERBER,  CLAYTON  G. LOOSLI,  AND DOROTHY  ~RB  635 
infiltrated with cells. In the inflammatory areas no bacteria were seen micro- 
scopically or demonstrated on culture. 
Text-fig.  2 also shows the growth curves of PR8-S and PR8-T~I virus in the 
lungs of mice immunized with PR8-S vaccine.  The solid homologous immunity 
is reflected by the absence of detectable virus in the lungs of vaccinated mice 
exposed to PRS-S virus.  The variant  strain,  on  the other hand,  multiplied 
rapidly and reached a maximum titer of 10  ~-s EIDs0 at 48 hours. The rate of 
virus multiplication during the first 24 hour period, as indicated by the slope 
of the curves, is somewhat lower than that of the corresponding control. The 
virus content of the lungs decreased gradually after 72 hours and disappeared 
by the 8th day. 
None of the ~mmunized  animals  which were challenged  with  either virus 
died. Likewise, no gross or microscopic lesions could be seen in the lungs of the 
mice exposed to the air-borne cloud of homologous PRS-S virus. On the other 
hand,  spotted areas of consolidation were seen in the lungs of the PRS-S-- 
immunized  animals  infected  with  the  variant  PRS-T~1 strain.  These  were 
noted in the lungs of mice killed at 3i 4, 5, 6, and 7 days after exposure to the 
nebulized  virus.  Microscopically the  p~llmonary  le~ions were  extensive  but 
focal in distribution. At 4 days as seen in Fig. 3, there was marked destruction 
of the bronchial l~n~ng cells and focal areas of exudation of leucocytes into the 
bronchial  lumina  and  alveolar  spaces  about  the  bronchi.  Only  occasional 
alveoli, however, showed a serous exudate. 
The results of the parallel experiment in mice vaccinated with the variant 
PR8-T~I  influenza  virus and  challenged  with PR8-S are illustrated  in Text- 
fig. 3. No homologous challenge virus (PRS-T20 was detectable in the lungs of 
immunized  mice,  whereas PRS-S virus after reaching  a  relatively low peak 
titer of 10  ~-e EID60 at 24 hours decreased rapidly and disappeared by the 4th 
day.  None  of  these  immunized  animals  which  were challenged  with  either 
virus died,  nor could gross or microscopic lesions  be seen in  the ~mmunized 
mice challenged  with the homologous (PRg-Tm) virus. Gross pulmonary lesions 
also were not detected in the lungs of the mice infected with the heterologous 
(PRS-S) virus, and as seen in Fig. 4 only minimal changes were noted in the 
bronchial lining  ceils in the animals killed at 2, 3, and 4 days after exposure 
to the virus cloud. There was no involvement of the alveolar walls and spaces. 
DISCUSSION 
Antigenic analyses by HUleman  (18) and Magill and Jotz (19) of influenza 
A strains isolated during  the period of 1933-51  revealed the occurrence of a 
progressive change of antigenic characteristics over the 18 year period. They 
showed that  antigenic complexes  prevalent in older strains were replaced or 
obscured by antigenic  components appearing  in  the more  recently isolated 636  ANTIGENIC  VARIANTS  OF  IN]VLUENZA  A  VIRUS 
strains which reacted only weakly with antisera against the earlier ones, never- 
theless retaining  the capacity to elicit antibodies to  them.  The  use  of  the 
antibody absorption technique in the study of antigenic complexes of influenza 
A viruses enabled Jensen and Francis (14) to demonstrate clearly the quanti- 
tative and  qualitative differences  in antigenic components of strains  isolated 
in different years. The data presented in the present paper furnish experimental 
evidence for these epidemiological  findings. 
Successful  transmission  of the PR8 virus in  the immunized  mice was de- 
pendent on the initial selection  of animals with uniformally low H.I. antibody 
titers, determined from tail vein blood, and the intranasal instillation of suffi- 
cient  virus to provide a  survival advantage for those virus particles  whose 
antigenic character corresponded least with the antibodies present. With serial 
lung passage of the PR8 virus in  immunized  mice with increasingly  higher 
antibody  titers,  variant  strains  emerged  after  17  passages  which  differed 
markedly from  the parent  strain.  This is shown by the fact  that  following 
homologous challenge  with  either  the parent  (PRS-S)  or variant  (PRS-T21) 
strain no growth of virus occurred while following heterologous challenge virus 
growth occurred in both groups but was much greater in the lungs of the im- 
munized  (PRS-S) mice which  were challenged  with the PRS-T21 strain.  The 
extent of cross-protection afforded by vaccination with the parent or variant 
strains against infection was predictable from the comparative serological and 
immunological  data. That these variant strains were stable and independent of 
the  selective environment  was shown  by the  persistence  of  their  antigenic 
character following 12 serial passages in the lungs of normal mice. 
Of epidemiological  interest is the observation that mice vaccinated with the 
PR8-S vaccine which resulted in high antibody levels were not protected from 
marked  pulmonary  infections as indicated  by virus growth  and  pulmonary 
consolidation when allowed to breathe a cloud of variant PR8-T2~ virus. This 
approach of the immunological  selection  of antigenic variants in the presence 
of homologous antibody is being continued. Variants derived from variants are 
under study in an effort to gain a better understanding of the mechanism and 
significance of antigenic changes in influenza A viruses. Comparative serological 
studies of variants of variants with the original  PR8 virus indicate still fur- 
ther deviation of their antigenic make-up. 
In a study of this nature the possible danger of a "laboratory pick-up" of a 
variant strain of influenza virus, as emphasized  by Andrewes (17), always must 
be kept in mind. The following facts and observations, in our opinion,  rule out 
any possible laboratory contamination,  either  from  stock viruses or human 
sources: (6) during  the period of investigation only the mouse-adapted PR8 
strain  of influenza  A  virus was handled  in  this  laboratory;  (b)  there  was a 
stepwise increase  of a  "new" antigenic  component during  serial  passage of PAUL GERBER, CLAYTON  G. LOOSLI, AND DOROTHY  HAMEE  637 
PR8 in immunized mice; and (c) the passage strains remained highly virulent 
for mice whereas freshly isolated strains from human sources are usually not 
pathogenic for mice. 
SU~M~,RY 
Antigenically  different  strains  of  mouse-adapted  PR8  influenza  A  virus 
have been produced by 17 serial passages of the virus in the lungs of mice im- 
munized with the homologous agent. Comparative serological  tests show that 
the variant strains share antigenic components with the parent strain but the 
dominant antigen is different. By means of antibody absorption it was shown 
that  the  "new" antigenic  component of the variant  was already present  in 
minor  amounts up  to  the eighth  passage and  thereafter  gained  prominence 
with continued passage in vaccinated mice. 
Groups of mice vaccinated with either the PR8-S or T2~ virus and having 
comparable antibody titers showed no growth of virus in the lungs following 
aid-borne  challenge  with  homologous strains.  On  the  other hand,  following 
heterologous air-borne  challenge  no deaths  occurred,  but virus  grew  in  the 
lungs of both groups of vaccinated mice. Almost unrestricted virus multiplica- 
tion  took place in  the lungs of mice vaccinated with the parent  strain  and 
challenged  with the PR8-T21 virus which resulted in extensive consolidation. 
Less virus grew in the lungs of the mice vaccinated with the variant strains 
and challenged  with the PR8-S virus. In these animals  only microscopic evi- 
dence of changes due to virus growth in the lungs was observed. 
The successful  serial  passage of PR8 influenza  A virus in immunized  ani- 
mals was dependent on the initial selection of mice with uniformly low H.L 
antibody titers as determined on tail blood, and the intranasal instillation of 
sufficient virus to favor the survival of those virus particles least related to the 
antibodies present. The epidemiological  implications of these observations are 
discussed briefly. 
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EXPLANATION  OF PLATES 
P~z~- 44 
Fio.  1.  Photomicrograph of a  section of lung of a mouse (unvaccinated control) 
sacrificed 4 days after exposure to a lethal cloud of PR8-S virus. The bronchial lining 
cells show extensive destruction. There is also widespread  exudation of edema fluid 
and  leucocytes  in  the  alveolar spaces  and  marked perivascular and  peribronchial 
cellular infiltration.  Hematoxylin-eosin-azure II stain.  ×  110. 
FIo. 2.  Photomicrograph of a  section of lung of a mouse (unvaccinated control) 
sacrificed 4 days after exposure to a lethal cloud of PRS-T21 virus. The microscopic 
findings are the same as those described  in Fig. 1. Hematoxylin-eosin-azure II stain. 
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FIG.  3,  Photomicrograph of a section of lung of a  mouse immunized with PR8-S 
vaccine and killed 4  days  after  air-borne  challenge with  PR8-T,21 virus. Note  the 
marked destruction of the bronchial lining cells and the focal distribution of exudate 
in the peribronchial alveoli.  Hematoxylin-eosin-azure II stain.  X  110. 
FIG. 4.  Photomicrograph of a section of lung of a mouse immunized with  PRS-T,21 
vaccine and killed 4  days after air-borne challenge with  PRS-S  virus. The  inflam- 
matory  process  is  restricted  to  minor  changes  in  the  bronchial lining cells,  the 
alveolar portion remaining unaffected. Hematoxylin-eosin-azure  II stain.  X  l 10. THE  JOURNAL  OY  EXPERIMENTAL  MEDICINE  VOL.  101  PLATE  45 
(Gerber eta/.:  Antigenic variants of influenza A  virus) 